479 Jessie St , San Francisco, CA
It can take $10 billion to bring a drug to market today. The high cost of R&D and regulatory trials continue to increase while passing along those costs to the individuals whose lives are on the line.
Join us in exploring how technology can make drugs better and cheaper. These startups are making universal anti-venoms, antibiotics, cancer drugs, and transgenic organisms for more accurate animal models.
Come ask your questions and network with biotech professionals. Drinks and light snacks served.
Dan Dempsey, CEO of Venomyx
Venomyx is bringing antivenom into the 21st century with the world’s first toxin-specific snake antivenom. Their solution will make antivenom treatment safe, effective, and affordable for the millions of snakebite victims per year around the world that are currently underserved.
Edward Painter, CEO of A2A Pharma
A2A Pharmaceuticals designs computationally pre-optimized small molecule therapeutics for the treatment of cancer and antibiotic resistant bacterial infections.
Arshia Firouzi, CEO of Ravata Solutions
Ravata Solutions is transforming transgenic model development through automation with an aim of increasing pre-clinical medical discovery and innovation by 10–100x.